{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:31:26Z","timestamp":1784824286552,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T00:00:00Z","timestamp":1595030400000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["CDA2-003-10S"],"award-info":[{"award-number":["CDA2-003-10S"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.heliyon.2020.e04528","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T08:27:30Z","timestamp":1595924850000},"page":"e04528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Randomized feasibility trial to assess tolerance and clinical effects of lithium in progressive multiple sclerosis"],"prefix":"10.1016","volume":"6","author":[{"suffix":"II","given":"John R.","family":"Rinker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Meador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9391-7464","authenticated-orcid":false,"given":"Peter","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2020.e04528_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/01.wnl.0000335765.55346.fc","article-title":"Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis","volume":"72","author":"Altmann","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2020.e04528_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.biopsych.2006.10.027","article-title":"Greater cortical gray matter density in lithium-treated patients with bipolar disorder","volume":"62","author":"Bearden","year":"2007","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.heliyon.2020.e04528_bib3","series-title":"BDI-II: Beck Depression Inventory Manual","author":"Beck","year":"1996"},{"key":"10.1016\/j.heliyon.2020.e04528_bib4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1177\/1352458508094398","article-title":"Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study","volume":"14","author":"Brochet","year":"2008","journal-title":"Mult. Scler."},{"issue":"15","key":"10.1016\/j.heliyon.2020.e04528_bib5","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1073\/pnas.96.15.8745","article-title":"Lithium activites the serine\/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons","volume":"96","author":"Chalecka-Franaszek","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2020.e04528_bib6","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/archneur.58.6.961","article-title":"Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial","volume":"58","author":"Cohen","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.heliyon.2020.e04528_bib7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"NEJM"},{"key":"10.1016\/j.heliyon.2020.e04528_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4049\/jimmunol.181.1.338","article-title":"Lithium prevents and ameliorates experimental autoimmune encephalomyelitis","volume":"181","author":"De Sarno","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2020.e04528_bib9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/brain\/awh118","article-title":"Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts","volume":"127","author":"DeLuca","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.heliyon.2020.e04528_bib10","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","article-title":"Measuring the functional impact of fatigue: initial validation of the fatigue impact scale","volume":"18","author":"Fisk","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2020.e04528_bib11","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1073\/pnas.0708022105","article-title":"Lithium delays progression of amyotrophic lateral sclerosis","volume":"105","author":"Fornai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2020.e04528_bib12","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/1352458508093617","article-title":"Magnetic resonance imaging measures of brain and spinal cord atrohy correlate with clinical impairment in secondary progressive multiple sclerosis","volume":"14","author":"Furby","year":"2008","journal-title":"Mult. Scler."},{"key":"10.1016\/j.heliyon.2020.e04528_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3233\/JAD-190197","article-title":"Lithium as a treatment for Alzheimer\u2019s disease: the systems pharmacology perspective","volume":"69","author":"Hampel","year":"2019","journal-title":"J.\u00a0Alzheimer's Dis."},{"key":"10.1016\/j.heliyon.2020.e04528_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/01.WNL.0000149516.30155.B8","article-title":"Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a","volume":"64","author":"Hardmeier","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2020.e04528_bib15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2020.e04528_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tibs.2003.12.004","article-title":"The glamour and gloom of glycogen synthase kinase-3","volume":"29","author":"Jope","year":"2004","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.heliyon.2020.e04528_bib17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2020.e04528_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.msard.2017.08.019","article-title":"Evaluation of lithium serum level in multiple sclerosis patients: a neuroprotective element","volume":"17","author":"Karimi","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.heliyon.2020.e04528_bib19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1124\/mol.108.052357","article-title":"Lithium increases synapse formation between hippocampal neurons by depleting phosphoinositides","volume":"75","author":"Kim","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.heliyon.2020.e04528_bib20","first-page":"185","article-title":"Assessing fatigue in multiple sclerosis: Dutch modified fatigue impact scale","volume":"103","author":"Kos","year":"2003","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.heliyon.2020.e04528_bib21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awh721","article-title":"The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease","volume":"129","author":"Kremenchutzky","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.heliyon.2020.e04528_bib22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2020.e04528_bib23","first-page":"515","article-title":"Lithium treatment for bipolar disorder","volume":"78","author":"Mitchell","year":"2000","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.heliyon.2020.e04528_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"NEJM"},{"key":"10.1016\/j.heliyon.2020.e04528_bib25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions t the \u201cMcDonald Criteria","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.heliyon.2020.e04528_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0304-3940(02)00615-8","article-title":"Increased gray matter volume in lithium-treated bipolar disorder patients","volume":"329","author":"Sassi","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.heliyon.2020.e04528_bib27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/bmj.c332","article-title":"Consort 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2020.e04528_bib28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nimg.2002.1040","article-title":"Accurate, robust and automated longitudinal and cross-sectional brain change analysis","volume":"17","author":"Smith","year":"2002","journal-title":"Neuroimage"},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2020.e04528_bib29","first-page":"12","article-title":"Interplay between mechanisms of damage and repair in multiple sclerosis","volume":"255","author":"Stadelmann","year":"2008","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.heliyon.2020.e04528_bib30","series-title":"Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-Up of MS","author":"Traboulsee","year":"2003"},{"key":"10.1016\/j.heliyon.2020.e04528_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A\u00a0health related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.heliyon.2020.e04528_bib32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3233\/JAD-190862","article-title":"NPO3, a microdose lithium formation, blunts early amyloid post-plaque neuropathology in McGill-R-Thy1-APP Alzheimer-like transgenic rats","volume":"73","author":"Wilson","year":"2020","journal-title":"J.\u00a0Alzheimer's Dis."},{"key":"10.1016\/j.heliyon.2020.e04528_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/01.wnl.0000316810.01120.05","article-title":"Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis","volume":"71","author":"Zivadinov","year":"2008","journal-title":"Neurology"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020313724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020313724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:49:56Z","timestamp":1776214196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844020313724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2405844020313724"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04528","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized feasibility trial to assess tolerance and clinical effects of lithium in progressive multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e04528"}}